Cerdulatinib is an oral, dual inhibitor of SYK and JAK kinases currently under investigation as an anti-cancer agent, particularly for the treatment of relapsed or refractory peripheral T-cell lymphoma.… Read more
Cerdulatinib is an oral, dual inhibitor of SYK and JAK kinases currently under investigation as an anti-cancer agent, particularly for the treatment of relapsed or refractory peripheral T-cell lymphoma. This category offers a comprehensive selection of high-quality reference standards, including the active pharmaceutical ingredient, to support rigorous pharmaceutical analysis. Laboratory professionals utilize these compounds for critical tasks such as impurity profiling, the detection of nitroso derivatives, and the characterization of process-related degradation products like N-oxides and dioxides. Additionally, stable isotope labelled versions of Cerdulatinib are available to serve as internal standards for accurate quantification in complex biological matrices. These materials are essential tools for method development, validation, and routine quality control, ensuring compliance with analytical requirements throughout the drug development and manufacturing lifecycle.